These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 28692295)

  • 1. Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.
    Crew AP; Raina K; Dong H; Qian Y; Wang J; Vigil D; Serebrenik YV; Hamman BD; Morgan A; Ferraro C; Siu K; Neklesa TK; Winkler JD; Coleman KG; Crews CM
    J Med Chem; 2018 Jan; 61(2):583-598. PubMed ID: 28692295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
    Zoppi V; Hughes SJ; Maniaci C; Testa A; Gmaschitz T; Wieshofer C; Koegl M; Riching KM; Daniels DL; Spallarossa A; Ciulli A
    J Med Chem; 2019 Jan; 62(2):699-726. PubMed ID: 30540463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
    Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders.
    Lu J; Huang Y; Huang J; He R; Huang M; Lu X; Xu Y; Zhou F; Zhang Z; Ding K
    J Med Chem; 2022 Feb; 65(3):2313-2328. PubMed ID: 35084180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
    Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
    ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.
    Chan KH; Zengerle M; Testa A; Ciulli A
    J Med Chem; 2018 Jan; 61(2):504-513. PubMed ID: 28595007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
    Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
    ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Biological Evaluation of MEK PROTACs.
    Vollmer S; Cunoosamy D; Lv H; Feng H; Li X; Nan Z; Yang W; Perry MWD
    J Med Chem; 2020 Jan; 63(1):157-162. PubMed ID: 31804822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent small molecule PROTACs targeting mutant EGFR.
    Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen.
    Loren G; Espuny I; Llorente A; Donoghue C; Verdaguer X; Gomis RR; Riera A
    Eur J Med Chem; 2022 Dec; 243():114770. PubMed ID: 36148710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of PROTAC cooperative recognition for selective protein degradation.
    Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
    Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent Ligands for Protein Degradation in Drug Discovery.
    Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
    Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
    Wang C; Zhang Y; Wang J; Xing D
    Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
    Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
    J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ternary Complex-Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo-PROTACs.
    Diehl CJ; Salerno A; Ciulli A
    Angew Chem Int Ed Engl; 2024 Jun; 63(25):e202319456. PubMed ID: 38626385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
    Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
    J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
    Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
    Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.